Molecular Dx

U.K. researchers detail how early-stage melanomas at risk of spreading secrete a growth factor, TGFβ2, that causes downregulation of the proteins AMBRA1 and Loricrin—both of which are found in the skin overlaying the tumor.

NS2 protein identified as factor that prevents long-term inflammation from respiratory syncytial virus and possibly other respiratory viruses.

Central to the deal was GeneDx’s rare disease diagnosis and clinical exome sequencing capabilities along with data from more than 300,000 exomes and 2.1 million annotated patient phenotypes.

New Guinness world record for human genome sequencing of less than 6 hours, set at Stanford University using Oxford Nanopore's sequencing technology, helps identify genetic disease in less than 8 hours.

A tool that can pinpoint the location of detailed immune cell types in the human gut and lymph node, as well as map the fine-grained structure of the mouse brain has been developed by researchers based at the Wellcome Sanger Institute.

A new study by researchers from the department of twin research and genetic epidemiology, King’s College London, and the NIHR BioResource, has revealed genetic pathways underlying obesity.

The four-marker protein panel (4MP) includes four proteins—the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fragment—that have previously shown potential to identify people at risk of developing lung cancer.

MeMed’s core technology—it’s MeMed BV test run on the MeMed Key testing platform—is able to quickly distinguish whether a patient has a bacterial or a viral infection to allow physicians to either properly prescribe antibiotics, when needed, but also to avoid prescribing them if a patient is suffering from a viral infection.

According to the companies, the consortium will create an infrastructure capable of analyzing and cataloging one billion peptides each year, data which should lead to the identification of new protein variants and novel biomarkers, as targets for the development of potential new therapies.

Through research done mostly in a mouse model, Canadian scientists have identified a biomarker, soluble E-selectin, that could be used to test whether women, but not men, have neurovascular signs of depression.